# 2026-08587: ANI Pharma's Bid to Import Key Controlled Drugs

2026-08587, Importer of Controlled Substances Application: ANI Pharmaceuticals Inc., is a Federal Register notice from Justice Department, Drug Enforcement Administration published 2026-05-04, effective Registered bulk manufacturers of the affected basic class(es), and applicants, therefore, may submit electronic comments on or objections to the issuance of the proposed registration on or before June 3, 2026. Such persons may also file a written request for a hearing on the application on or before June 3, 2026.; PRIA reads it as touching household money (as of 2026-06-08).

- Canonical: https://policyrisk.com/federal-register/2026-08587
- As of: 2026-06-08
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-08587
- Title: Importer of Controlled Substances Application: ANI Pharmaceuticals Inc.
- Type: Notice
- Agencies: Justice Department; Drug Enforcement Administration
- Citation: 91 FR 24008
- Published: 2026-05-04
- Effective: Registered bulk manufacturers of the affected basic class(es), and applicants, therefore, may submit electronic comments on or objections to the issuance of the proposed registration on or before June 3, 2026. Such persons may also file a written request for a hearing on the application on or before June 3, 2026.
- Comments close: 2026-06-03
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-06-08

## In one line

ANI Pharma's Bid to Import Key Controlled Drugs

## Summary

ANI Pharmaceuticals wants to import certain controlled drugs like Levorphanol and Tapentadol. People who make or use these drugs can share their thoughts or ask for a hearing by June 3, 2026. This move could affect drug availability and regulation, so keep an eye on the deadline to have your say!

## Abstract

ANI Pharmaceuticals Inc. has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to SUPPLEMENTARY INFORMATION listed below for further drug information.

## Effects PRIA read

- Comment and Hearing Deadline: benefit, low. Registered bulk manufacturers and applicants may submit electronic comments or objections, or file a written request for a hearing, on ANI Pharmaceuticals Inc.'s importer application by June 3, 2026. Comments must be submitted through Regulations.gov or hearing requests sent to the DEA addresses li…
- Levorphanol Import Authorization Sought: benefit, low. ANI Pharmaceuticals applied to be registered to import Levorphanol (controlled substance code 9220, Schedule II) for distribution to customers. If the registration is granted, this import authorization would cover Levorphanol distribution as described in the application.
- Tapentadol Import Limited to Research: cost, low. ANI applied to import Tapentadol (controlled substance code 9780, Schedule II) only in small quantities for internal research and reference standards purposes. The application states no other activities for this drug code are authorized for this registration.
- No Import of Finished Dosage Forms: cost, medium. The notice states that authorization for this import registration will not extend to the import of Food and Drug Administration-approved or non-approved finished dosage forms for commercial sale. Permit approval will be limited to activities consistent with 21 U.S.C. 952(a)(2).

## Related documents

- [2026-11526](https://policyrisk.com/federal-register/2026-11526): Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 201…, 2026-06-09
- [2026-10128](https://policyrisk.com/federal-register/2026-10128): Revision of Applications for Manufacturing and Procurement Quotas, 2026-05-20
- [2025-05007](https://policyrisk.com/federal-register/2025-05007): Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients, 2025-03-24
- [2025-02793](https://policyrisk.com/federal-register/2025-02793): Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients, 2025-02-19
- [2026-22843](https://policyrisk.com/federal-register/2026-22843): Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ep…, 2026-11-10
- [2026-22842](https://policyrisk.com/federal-register/2026-22842): Adjustment to the 2026 Aggregate Production Quota for d,l-Amphetamine, d-Amphetamine (for Sale), Hydromorphone and Methylphenidate (for Sal…, 2026-11-10

## Sources
- [2026-08587 on federalregister.gov](https://www.federalregister.gov/documents/2026/05/04/2026-08587/importer-of-controlled-substances-application-ani-pharmaceuticals-inc)
- [2026-08587 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-05-04/pdf/2026-08587.pdf)

## Related
- [Previous: 2026-08586, Bulk Manufacturer of Controlled Substances Application: ANI Pharmaceuticals Inc.](https://policyrisk.com/federal-register/2026-08586)
- [Next: 2026-08588, Bulk Manufacturer of Controlled Substances Application: Patheon API Inc.](https://policyrisk.com/federal-register/2026-08588)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-08587 (as of 2026-06-08).
